Clinical trial
Study of Epratuzumab in Systemic Lupus Erythematosus
NCT00111306 · UCB Pharma, Industry · Terminated
Key facts
| NCT number | NCT00111306 |
|---|---|
| Title | Study of Epratuzumab in Systemic Lupus Erythematosus |
| Official title | A Phase III, Randomized, Double-Blind. Placebo-Controlled, Multi-Center Study of Systemic Lupus Erythematosus With Acute Severe SLE Flares Excluding Renal or Neurological Systems |
| Lead sponsor | UCB Pharma, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Systemic Lupus Erythematosus |
| Intervention type | Drug |
| Interventions | epratuzumab |
| Enrollment | 510 |
| Start date | Jun 1, 2005 |
| Primary completion | Mar 1, 2007 |
| Completion | Mar 1, 2007 |
| First posted | May 20, 2005 |
| Last update posted | Nov 8, 2011 |
| Countries | Belgium, Hungary, Netherlands, Spain, United Kingdom, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: